#AIDS2018: Mylan’s Commitment to Patients Living With HIV

August 24, 2018

Mylan’s longstanding commitment to patients living with HIV was on display at International AIDS 2018, the largest healthcare conference in the world. A sponsor of the event, Mylan also hosted a symposium and met with key opinion leaders and international media, all in the spirit of sharing ideas about how innovation and access can help patients around the world. The event focused on the role of low-cost antiretrovirals (ARVs) in high-, middle- and low-income countries.

For more than a decade, Mylan has been a leader in providing access to quality, dependable and affordable ARVs in 100 countries around the world. More than 40% of the nearly 21 million HIV+ patients being treated today – and 60% of the world’s HIV+ children – depend on a Mylan product.

Mylan CEO Heather Bresch said at the conference that Mylan is committed to serving all patients, and that the balance of innovation and competition will drive access to these important medicines.

Also at the conference, Bresch and Anil Soni, Mylan’s head of Global Infectious Disease, talked about achieving the UNAIDS 90-90-90 goals by 2020. Set in 2014, the goals aim to diagnose 90% of all HIV-positive persons, provide ARV therapy for 90% of those diagnosed, and achieve viral suppression for 90% of those treated by 2020.

Bresch said to achieve those goals, treatment must be affordable, and we must continue to innovate to meet patient needs. She also advocated for easier diagnostic tools, such as Mylan’s HIV Self Test, which is currently only available in Belgium, France, Ireland, Italy, Romania and Spain.

Learn more about Mylan's work with infectious disease here. Watch this video to learn more about Mylan's commitment to people living with HIV/AID